AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25968622 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic bilateral adrenalectomy (LBA)
Number of subjects: 28
Study 25968826 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy (IMRT 63 Gy/35 fractions, chemotherapy with paclitaxel 45 mg/m² and carboplatin AUC=2 for 7 weeks)
Number of subjects: 48
Study 25968826 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy
Number of subjects: 48
Study 25969178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Gel
Number of subjects: 144
Study 25969178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tablets
Number of subjects: 144
Study 25969545 — intervention group
Group type: EXPERIMENTAL
Intervention: Supera stent (interwoven-wire design)
Number of subjects: 264
Study 25969833 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0
Study 25969833 — intervention group
Group type: COMPARATOR
Intervention: Statistical model without pharmacodynamics
Number of subjects: 0
Study 25970800 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 11466
Study 25970800 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11466
Study 25970800 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 11466
Study 25970800 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 11466
Study 25970800 — intervention group
Group type: COMPARATOR
Intervention: Nonmethotrexate/nonbiologics
Number of subjects: 11466
Study 25970800 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate/nonbiologics
Number of subjects: 11466
Study 25970800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment cohorts
Number of subjects: 11466
Study 25971341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic markers for outcome prediction in anoxic coma
Number of subjects: 172
Study 25971341 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates adjusted for age and sex
Number of subjects: 172
Study 25971341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed effects regression models (fixed and random effects)
Number of subjects: 172
Study 25971341 — intervention group
Group type: EXPERIMENTAL
Intervention: Null hypothesis testing
Number of subjects: 172
Study 25971341 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon's two-stage design
Number of subjects: 172
Study 25971721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral protein intake ≥60% of the prescribed goal
Number of subjects: 1245
Study 25971721 — intervention group
Group type: COMPARATOR
Intervention: Enteral protein intake <20% of the prescribed goal
Number of subjects: 1245
Study 25971721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean enteral protein delivery
Number of subjects: 1245
Study 25971791 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding perceived barriers to documentation
Number of subjects: 55
Study 25971791 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding institutional management of data
Number of subjects: 55
Study 25971791 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of anaesthesia staff regarding attitudes towards data usefulness
Number of subjects: 55
Study 25971886 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT) 0.25 μg/kg in Group O (old age group)
Number of subjects: 42
Study 25971886 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT) 0.35 μg/kg in Group Y (young age group)
Number of subjects: 42
Study 25971886 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dexmedetomidine (DMT)
Number of subjects: 42
Study 25972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 104
Study 25972018 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 104
Study 25972188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution testing using Determine™ rapid diagnostic test at 1/160 dilution
Number of subjects: 2895
Study 25972188 — intervention group
Group type: COMPARATOR
Intervention: RDT diagnostic algorithm
Number of subjects: 2895
Study 25972258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus Autofluorescence Imaging (FAF) and Near Infrared (NIR) reflectance imaging
Number of subjects: 36
Study 25972523 — intervention group
Group type: EXPERIMENTAL
Intervention: Midupper Arm Circumference (MUAC)
Number of subjects: 721
Study 25972523 — intervention group
Group type: EXPERIMENTAL
Intervention: Midupper Arm Circumference z score (MUACZ)
Number of subjects: 721
Study 25972523 — intervention group
Group type: COMPARATOR
Intervention: Weight-for-age z score (WAZ)
Number of subjects: 721
Study 25972523 — intervention group
Group type: COMPARATOR
Intervention: Weight-for-length z score (WLZ)
Number of subjects: 721
Study 25972528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary choline intake
Number of subjects: 368
Study 25972528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma concentrations of betaine, dimethylglycine, and TMAO
Number of subjects: 368
Study 25972528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake and fetal genetic variants
Number of subjects: 368
Study 25972901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (67-150 mg/m²/day)
Number of subjects: 13
Study 25973150 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 250 mg capsules (bid)
Number of subjects: 30
Study 25973150 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 30
Study 25973421 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary transposed brachio-basilic vein (TBBV) fistula
Number of subjects: 16
Study 25973421 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged TBBV fistula
Number of subjects: 16
Study 25973421 — intervention group
Group type: COMPARATOR
Intervention: Primary TBBV fistula
Number of subjects: 16
Study 25973678 — intervention group
Group type: EXPERIMENTAL
Intervention: Foaming facial wash and SPF 30 moisturizer
Number of subjects: 35
Study 25974030 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin added to basal insulin
Number of subjects: 247
Study 25974030 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 247
Study 25974235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy
Number of subjects: 0
Study 25974382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, dexamethasone and cyclophosphamide
Number of subjects: 28
Study 25975390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol anesthesia clinically titrated by providers blinded to BIS
Number of subjects: 26
Study 25975390 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed maintenance dosing regimen targeting BIS of 50 ± 10
Number of subjects: 26
Study 25975390 — intervention group
Group type: EXPERIMENTAL
Intervention: PK/PD models for children/obese adults (PK:Eleveld/PD:Cortinez)
Number of subjects: 26
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFS
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: PSFS
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: WPAI: SHP (daily activities impairment portion)
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: PGIC
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: PGAR
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 20
Study 25975429 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 20
Study 25975848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 111
Study 25975934 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir every 8 hours for 6 days
Number of subjects: 24
Study 25975934 — intervention group
Group type: COMPARATOR
Intervention: Healthy control volunteers
Number of subjects: 24
Study 25975975 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin with ATRA (PETHEMA/HOVON cohort)
Number of subjects: 525
Study 25975975 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin with ATRA (IC-APL cohort)
Number of subjects: 525
Study 25976268 — intervention group
Group type: EXPERIMENTAL
Intervention: PED-based smoking cessation intervention (counseling, referral to Quitline, free nicotine replacement therapy)
Number of subjects: 200
Study 25976268 — intervention group
Group type: EXPERIMENTAL
Intervention: PED-based smoking cessation intervention
Number of subjects: 200
Study 25976713 — intervention group
Group type: EXPERIMENTAL
Intervention: eVLU (internet-based learning program)
Number of subjects: 0
Study 25976713 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 25976760 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of intimate partner violence (IPV) after HIV infection
Number of subjects: 19
Study 25976760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways leading to IPV
Number of subjects: 19
Study 25976768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (first and second courses)
Number of subjects: 50
Study 25976768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (multiple courses)
Number of subjects: 50
Study 25976768 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP-3α biomarker
Number of subjects: 50
Study 25976768 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (untreated)
Number of subjects: 50
Study 25977111 — intervention group
Group type: COMPARATOR
Intervention: Coronary CT angiography (CTA) alone
Number of subjects: 381
Study 25977111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion (CTP)
Number of subjects: 381
Study 25977197 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBehavior's personalized suggestions (n=9)
Number of subjects: 17
Study 25977197 — intervention group
Group type: COMPARATOR
Intervention: Nonpersonalized suggestions (n=8)
Number of subjects: 17
Study 25977266 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg once daily), asunaprevir (100 mg twice daily), peg-IFN/RBV after a 4-week lead-in phase with peg-IFN/RBV for a total of 24 weeks.
Number of subjects: 75
Study 25977266 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir, asunaprevir, peg-IFN/RBV
Number of subjects: 75
Study 25977304 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25977463 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT
Number of subjects: 25
Study 25977584 — intervention group
Group type: EXPERIMENTAL
Intervention: iC9-T cells
Number of subjects: 12
Study 25977584 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 (CID)
Number of subjects: 12
Study 25977584 — intervention group
Group type: EXPERIMENTAL
Intervention: CID
Number of subjects: 12
Study 25977882 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-DOTA-peptides PET/CT
Number of subjects: 27
Study 25977884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg once daily for 8 days)
Number of subjects: 6
Study 25977884 — intervention group
Group type: COMPARATOR
Intervention: Baseline scan
Number of subjects: 6
Study 25977884 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 8 scan
Number of subjects: 6
Study 25978152 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour shifts
Number of subjects: 1
Study 25978152 — intervention group
Group type: COMPARATOR
Intervention: 24-hour shifts
Number of subjects: 1
Study 25979098 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 65-75 (light sedation)
Number of subjects: 108
Study 25979098 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 50-60 (deep sedation)
Number of subjects: 108
Study 25979098 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided propofol infusion
Number of subjects: 108
Study 25979109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed colonic inflammatory bowel disease (IBD) mucosa
Number of subjects: 0
Study 25979109 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBS colitis
Number of subjects: 0
Study 25979109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed samples
Number of subjects: 0
Study 25979109 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of GUCA2A and GUCY2C
Number of subjects: 0
Study 25979109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcription factor CDX2
Number of subjects: 0
Study 25979230 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 12
Study 25979230 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + FOLFOX chemotherapy
Number of subjects: 12
Study 25979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel immune-specific systemic therapies
Number of subjects: 0
Study 25979390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput sequencing technologies
Number of subjects: 0
Study 25979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Discovery of human papillomavirus
Number of subjects: 0
Study 25979539 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed of high-risk status by health professional
Number of subjects: 59
Study 25979539 — intervention group
Group type: COMPARATOR
Intervention: Not informed of high-risk status by health professional
Number of subjects: 59
Study 25979786 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily for 3 months, then daily for 3 months)
Number of subjects: 120
Study 25979786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 120
Study 25979867 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation system for intravenous thrombolysis
Number of subjects: 300
Study 25979867 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care quality in spoke hospitals without guidance from the hub hospital
Number of subjects: 300
Study 25980594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240-1120 mg or 960 mg orally twice daily
Number of subjects: 48
Study 25980594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib continued after local therapy
Number of subjects: 48
Study 25980594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib treatment duration beyond initial PD
Number of subjects: 48
Study 25980594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 48
Study 25980753 — intervention group
Group type: COMPARATOR
Intervention: Lugol's chromoendoscopy (LCE)
Number of subjects: 147
Study 25980753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (LCE) + High-Resolution Microendoscope (HRME)
Number of subjects: 147
Study 25980753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscope (HRME)
Number of subjects: 147
Study 25980755 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (GE)
Number of subjects: 78
Study 25980755 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT baseline HbA1c
Number of subjects: 78
Study 25980755 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of DM before DCCT
Number of subjects: 78
Study 25980755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1c during DCCT-EDIC
Number of subjects: 78
Study 25980755 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 78
Study 25980755 — intervention group
Group type: COMPARATOR
Intervention: Normal gastric emptying
Number of subjects: 78
Study 25980755 — intervention group
Group type: COMPARATOR
Intervention: Delayed gastric emptying
Number of subjects: 78
Study 25980755 — intervention group
Group type: COMPARATOR
Intervention: Rapid gastric emptying
Number of subjects: 78
Study 25981169 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant erlotinib in patients with mutant EGFR
Number of subjects: 24
Study 25981169 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/carboplatin (GC) in patients with wild type EGFR
Number of subjects: 24
Study 25981490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination (Havrix(®) junior; GSK Vaccines, Belgium) with a two-dose schedule
Number of subjects: 42
Study 25981490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based active surveillance for hepatitis cases
Number of subjects: 42
Study 25981554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-expression classifier
Number of subjects: 639
Study 25981554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-expression classifier plus bronchoscopy
Number of subjects: 639
Study 25981814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (500 mg per day, orally, on a 5-days-on and 2-days-off schedule)
Number of subjects: 53
Study 25981813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg oral capsules once a day on a continuous basis in 28-day cycles
Number of subjects: 1227
Study 25982012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib and everolimus
Number of subjects: 1
Study 25982504 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (30 mg/kg)
Number of subjects: 20
Study 25982504 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study 25982653 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) using the Symplicity Flex™ catheter
Number of subjects: 63
Study 25982652 — intervention group
Group type: EXPERIMENTAL
Intervention: Symplicity multi-electrode radiofrequency renal denervation system
Number of subjects: 50
Study 25982654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular prosthesis implant
Number of subjects: 1
Study 25983041 — intervention group
Group type: EXPERIMENTAL
Intervention: SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle
Number of subjects: 32
Study 25984873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy for 6.5 years
Number of subjects: 0
Study 25984873 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25984876 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intraarterial treatment plus usual care
Number of subjects: 0
Study 25984880 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotics
Number of subjects: 0
Study 25984880 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of antibiotics
Number of subjects: 0
Study 25985024 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal hernia repair
Number of subjects: 2929
Study 25985024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 2929
Study 25985024 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hysterectomy
Number of subjects: 2929
Study 25985024 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 2929
Study 25985024 — intervention group
Group type: COMPARATOR
Intervention: CPSP risk model
Number of subjects: 2929
Study 25985169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia induced by rapid infusion of 600-2000 mL cold saline combined with endovascular cooling
Number of subjects: 140
Study 25985169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 140
Study 25985169 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 140
Study 25985404 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy (ART)
Number of subjects: 325
Study 25985404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-based antiretroviral therapy (ART)
Number of subjects: 325
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for eclampsia
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for hemorrhage
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for obstructed labor
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal provider care seeking for sepsis
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall care seeking behavior
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors associated with care seeking from formal providers
Number of subjects: 9576
Study 25985774 — intervention group
Group type: EXPERIMENTAL
Intervention: Service factors associated with care seeking from formal providers
Number of subjects: 9576
Study 25985785 — intervention group
Group type: COMPARATOR
Intervention: Guidewire and microcatheter strategy
Number of subjects: 438
Study 25985785 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized CTO crossing device
Number of subjects: 438
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol as the sole induction agent
Number of subjects: 28
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol as the primary maintenance agent
Number of subjects: 28
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rates
Number of subjects: 28
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion duration
Number of subjects: 28
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Total doses of propofol
Number of subjects: 28
Study 25985870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to propofol
Number of subjects: 28
Study 25985882 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone with concomitant bone-targeted therapy (BTT)
Number of subjects: 0
Study 25985882 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study 25986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m2 weekly for 3 of 4 weeks
Number of subjects: 11